Vance E A, Soiffer R J, McDonald G B, Myerson D, Fingeroth J, Ritz J
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02146, USA.
Transplantation. 1996 Nov 15;62(9):1358-60. doi: 10.1097/00007890-199611150-00032.
Transmission of hepatitis C virus (HCV) in the setting of allogeneic bone marrow transplantation can occur through an infected marrow donor. Prevention of transmission may reduce the risks of peritransplant complications. We describe a 43-year-old patient with chronic myelogenous leukemia whose HLA-identical donor was found to be HCV antibody positive and HCV RNA positive by polymerase chain reaction (PCR). The patient was HCV antibody negative and HCV RNA negative by PCR of the serum. For 6 months before bone marrow transplantation, the donor was treated with alpha-interferon at a standard dose. After 3 months, HCV RNA was no longer detectable by PCR. Interferon was discontinued 1 week before harvest. Bone marrow cellularity was normal. Engraftment was prompt. The recipient's serum remained negative for HCV RNA at 1, 3, 5, and 10 months after transplantation. Hepatitis C transmission from a viremic donor to an HCV-seronegative recipient may be preventable by treating the donor with alpha-interferon.
在同种异体骨髓移植过程中，丙型肝炎病毒（HCV）可通过受感染的骨髓供体传播。预防传播可能会降低移植周围并发症的风险。我们描述了一名43岁的慢性粒细胞白血病患者，其HLA配型相同的供体经聚合酶链反应（PCR）检测发现HCV抗体阳性且HCV RNA阳性。该患者血清HCV抗体阴性且经PCR检测HCV RNA阴性。在骨髓移植前6个月，供体接受标准剂量的α干扰素治疗。3个月后，PCR检测不再能检测到HCV RNA。在采集前1周停用干扰素。骨髓细胞计数正常。植入迅速。移植后1、3、5和10个月，受者血清HCV RNA仍为阴性。通过用α干扰素治疗供体，可能可预防HCV从病毒血症供体传播至HCV血清学阴性的受者。
